Initiation of quarterly palmitate paliperidone in French clinical practice: Results from the observational, cross-sectional OPTIMUS study.
clinical study
paliperidone palmitate
patient profile
real-world
schizophrenia
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
02
11
2021
received:
05
07
2021
accepted:
09
12
2021
pubmed:
14
12
2021
medline:
26
3
2022
entrez:
13
12
2021
Statut:
ppublish
Résumé
Long-term antipsychotic treatment is key to a positive clinical outcome in schizophrenia. Recent guidelines recommend the prescription of long-acting antipsychotic formulations (LAIs) as early as the first episode in patients with schizophrenia. The OPTIMUS study evaluated real-world use of a new three-monthly paliperidone palmitate formulation (PP3M) in France. For this observational cross-sectional study, all French psychiatrists were invited to enrol patients who had initiated PP3M in the previous 4 months. Snapshot data were collected at a routine consultation, without any modification of clinical practice. This population of 350 patients with schizophrenia started on PP3M predominantly included single men, living independently with a diagnosis of schizophrenia for a median of 9.3 years. Demographic characteristics were broadly comparable to those reported in other studies on LAIs. Investigators cited treatment simplification (96.9%) and patient comfort (93.3%) as the most common reasons for switching to PP3M; enhancing adherence was mentioned less often (61.1%) with most patients previously considered as adherent, and a majority of them expressing a positive attitude to their treatment. One-third of patients accepted the psychiatrist's proposal to initiate PP3M treatment without any discussion, and relatives were involved in the therapeutic decision-making process in only 23.7% of cases. After initiation, few changes were seen in professional follow-up frequency or concomitant pharmacological and non-pharmacological treatment modalities except for a decrease in antipsychotic polytherapy. PP3M is mostly prescribed in adherent patients with fairly stable schizophrenia, and the longer dosing interval does not substantially affect patient care.
Substances chimiques
Antipsychotic Agents
0
Palmitates
0
Paliperidone Palmitate
R8P8USM8FR
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
334-342Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. Peer-Rev J Formul Manag. 2014;39(9):638-645.
Millan MJ, Andrieux A, Bartzokis G, et al. Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov. 2016;15(7):485-515.
Tiihonen J, Tanskanen A, Taipale H. Risk of treatment failure: response to Ghosh and Noble. Am J Psychiatry. 2018;175(12):1267-1267.
Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2-3):109-113.
Acosta FJ. Medication adherence in schizophrenia. World J Psych. 2012;2(5):74-82.
Fagiolini A, de Bartolomeis A, Vaggi M. Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics. Neuropsychiatr Dis Treat. 2016;12:99-108.
Tiihonen J, Walhbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224.
Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274-280.
Pompili M. Adding suicide prevention to the triple advantages of injectable long-acting second-generation antipsychotics. Front Psych. 2020;11:101.
Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs. 2011;25:845.
Gopal S, Vermeulen A, Nandy P, et al. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Curr Med Res Opin. 2015;31(11):2043-2054.
Weiden PJ, Kim E, Bermak J, Turkoz I, Gopal S, Berwaerts J. Does half-life matter after antipsychotic discontinuation?: a relapse comparison in schizophrenia with 3 different formulations of paliperidone. J Clin Psych. 2017;78(7):813-820.
Samalin L, Abbar M, Courtet P, Guillaume S, Lancrenon S, Llorca P-M. Recommandations formalisées d'Experts de l'AFPBN: prescription des neuroleptiques et antipsychotiques d'action prolongée. Encéphale. 2013;39:189-203.
Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psych. 2015;72(8):830-839.
Savitz AJ, Xu H, Gopal S, Nuamah I, Hough D, Mathews M. Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study. Int Clin Psychopharmacol. 2017;32(6):329-336.
Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialog Clin Neurosci. 2011;13(2):155-172.
Garcia-Portilla MP, Llorca P-M, Maina G, et al. Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia. Ther Adv Psychopharmacol. 2020;10:2634.
Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry. 2007;4(7):28-37.
Mallet J, Lancrenon S, Llorca P-M, Lançon C, Baylé F-J, Gorwood P. Validation of a four items version of the functional remission of general schizophrenia scale (the mini-FROGS) to capture the functional benefits of clinical remission. Eur Psych. 2018;47:35-41.
Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1-24.
Samalin L, de Chazeron I, Belzeaux R, Llorca P-M. Exploratory analysis of the French version of the beliefs about medicines questionnaire in patients with severe mental disorders: factorial structure and reliability in specific populations of schizophrenic, bipolar and depressive patients. PLoS One. 2017;12(3):267.
Grimaldi-Bensouda L, Rouillon F, Astruc B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the cohort for the general study of schizophrenia (CGS). Schizophr Res. 2012;134(2-3):187-194.
Limosin F, Belhadi D, Comet D, et al. Comparison of Paliperidone palmitate and risperidone long-acting injection in schizophrenic patients: results from a multicenter retrospective cohort study in France. J Clin Psychopharmacol. 2017;38:26.
Gorwood P, Bouju S, Deal C, et al. Predictive factors of functional remission in patients with early to mid-stage schizophrenia treated by long acting antipsychotics and the specific role of clinical remission. Psychiatry Res. 2019;281:112560.
Ziaaddini H, Kheradmand A, Vahabi M. Prevalence of cigarette smoking in schizophrenic patients compared to other hospital admitted psychiatric patients. Addict Heal. 2009;1(1):38-42.
Mallet J, Le Strat Y, Schürhoff F, et al. Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-schizophrenia cohort. Prog Neuropsychopharmacol Biol Psych. 2017;79:332-339.
Batel P. Addiction and schizophrenia. Eur Psych J Assoc Eur Psych. 2000;15(2):115-122.
Winklbaur B, Ebner N, Sachs G, Thau K, Fischer G. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci. 2006;8(1):37-43.
Volkow ND. Substance use disorders in schizophrenia-clinical implications of comorbidity. Schizophr Bull. 2009;35(3):469-472.
Pai N, Warden M. Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate. Australia Psych. 2018;26(6):628-634.
Hamann J, Mendel R, Cohen R, et al. Psychiatrists' use of shared decision making in the treatment of schizophrenia: patient characteristics and decision topics. Psych Serv. 2009;60(8):1107-1112.
Adams JR, Drake RE, Wolford GL. Shared decision-making preferences of people with severe mental illness. Psych Serv. 2007;58(9):1219-1221.